AUTOLOGOUS MORROW TRANSPLANTATION

本计划项目的总体目标是改善 自体骨髓移植治疗血液病 恶性肿瘤 本计划将涉及的一般主题 项目包括根除恶性肿瘤， 造血，外周血祖细胞对植入的影响， 生长因子的影响，并试图阻止体内生长抑制剂。 提出了七个独立的研究项目， 就这些主题进行合作： 1. AMT的评估。 a.急性淋巴细胞白血病和恶性淋巴瘤。 B.急性髓性白血病。 2.遗传标记的外周血再生细胞对 AMT后造血重建 3.造血生长因子：临床前评估。 4.集落形成细胞：从急性髓系白血病的前体细胞产生 白血病 5.克隆性造血：恶性肿瘤克隆性起源的评价， 造血 6.自体骨髓移植中的生长因子。 7.羊膜移植后促肾上腺皮质激素和免疫治疗的评价 我们开展本计划项目中提出的研究的能力是 通过以下方式增强：1）临床前研究计划，其集中于鼠， 犬或非人类灵长类动物模型，并允许快速和逻辑的翻译 临床前概念到临床试验，2）超过120 每年接受自体移植的患者进行研究，3） 生物统计学、骨髓处理、门诊等方面的支持性护理计划 以及长期随访、病理学、传染病咨询， 药理学、营养服务、输血支持和管理， 4）一个独特的结构，作为一个庞大的调查小组，所有人都是 集中在骨髓移植的一般性话题上。 成功 实现本计划项目的目标将与使用 其他强化疗法治疗血液恶性肿瘤， AMT在其他恶性肿瘤治疗中的应用， 非恶性疾病，以及全血细胞减少和 免疫功能低下的患者。

The overall goal of this Program Project is to improve the outcome of autologous marrow transplantation (AMT) in the treatment of hematologic malignancies. General topics which will be addressed by this Program Project include the eradication of malignancy, the clonality of hematopoiesis, the effects of peripheral blood progenitors on engraftment, effects of growth factors and attempts to block in vivo growth inhibitors. Seven individual research projects are proposed which will work collaboratively on these topics: 1.Evaluation of AMT. a.Acute lymphoblastic leukemia and malignant lymphoma. b.Acute myeloid leukemia. 2.Contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after AMT. 3.Hematopoietic growth factors: preclinical evaluation. 4.Colony Forming Cells: generation from precursors in Acute Myeloid Leukemia. 5.Clonal hematopoiesis: an evaluation of clonal origins in malignancy and hematopoiesis. 6.Growth factors in autologous marrow transplant. 7.Evaluation of Lymphokines and Adoptive immunotherapy following AMT. Our ability to carry out the studies proposed in this Program Project is enhanced by: 1) preclinical research programs which focus on murine, canine, or non-human primate models and allow rapid and logical translation of preclinical concepts to clinical trials, 2) the accrual of over 120 autologous transplant patients onto research studies each year, 3) supportive care programs in biostatistics, marrow processing, outpatient and long-term follow-up, pathology, infectious disease consulting, pharmacology, nutrition services, transfusion support and administration, and 4) a unique structure as a large group of investigators all of whom are focused on the general topic of marrow transplantation. Success in achieving the goals of this Program Project will have relevance for the use of other intensive therapies to treat hematologic malignancies, for the wider application of AMT in the treatment of other malignant and nonmalignant diseases, and for the care of pancytopenic and immunocompromised patients.